No Detail Found!

Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma

Author(s)
Yanxiao Kun Department of Surgery II, Suzhou Hospital of Integrated, Traditional Chinese and Western Medicine, Suzhou 215000, Jiangsu Province, P.R. China
Jian Wu Department of Surgery II, Suzhou Hospital of Integrated, Traditional Chinese and Western Medicine, Suzhou 215000, Jiangsu Province, P.R. China
Shaomu Chen Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 251000, Jiangsu Province, P.R. China
Abstract
Objective: To investigate the effects of EGFR-TKI combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage-IV lung adenocarcinoma. Methods: This retrospective observational study included 116 patients with stage-IV lung adenocarcinoma, treated in The First Affiliated Hospital of Soochow University from January 2021 to January 2022. According to the treatment records, 60 patients that received pemetrexed + cisplatin for four courses were set as a Control-group and 56 patients that received EGFR-TKI + pemetrexed + cisplatin for four courses were set as an Observation-group. Changes in immune function, tumor marker levels and oxidative stress level in the two groups were analyzed and compared. Results: After the treatment, levels of CD3+, CD4+, IgG and IgM in the Control-group were significantly lower than those before the treatment. EGFR-TKI + pemetrexed + cisplatin resulted in levels of CD3+, CD4+, IgG and IgM higher than before the treatment, and compared to the Control-group (p<0.001). After the treatment, the levels of NSE, serum CEA, serum CA125, CYFEA21-1 in both groups were significantly lower than those before treatment, and lower in the Observation-group (p<0.001). After the treatment, VEGF and MMP9 levels in both groups were significantly lower than those before treatment, and markedly lower in the Observation-group (p<0.001). Conclusion: Compared with systemic chemotherapy, EGFR-TKI targeted combined chemotherapy for stage-IV lung adenocarcinoma is associated with enhanced immune function of patients. It more effectively inhibits the growth and proliferation of tumor cells and reduces the level of oxidative stress.
Publication Details
Page(s) 742-746
Published Journal: Pakistan Journal of Medical Sciences, Volume: 39, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
immunity, Oxidative stress, Tumor Markers, Epidermal growth factor receptor, tyrosine kinase inhibitor, Targeting, Stage-IV lung adenocarcinoma
0

Citations

0

Downloads

79

Views